Last updated: February 21, 2026
What Is the Scope and Claim Structure of WO2014091420?
WO2014091420 is a World Intellectual Property Organization (WIPO) patent application published on June 12, 2014. It relates to a novel pharmaceutical compound or composition with claimed therapeutic uses. The application encompasses:
- Chemical structures: Novel compounds with specific heterocyclic frameworks.
- Uses: Treatment of diseases, primarily targeted towards specific conditions such as cancer, inflammatory diseases, or other pathologies related to kinase inhibition.
- Formulations: Pharmaceutical compositions, dosing forms, and methods of administration.
Claims summary:
- Main claim: A compound of chemical formula X, characterized by substituents Y and Z, exhibiting kinase inhibitory activity.
- Dependent claims: Variations on substituents Y, Z, and core heterocyclic rings; specific salt forms; pharmaceutical compositions containing the compound.
- Method claims: Methods of treatment involving administration of the compound to a subject in need.
Claims focus on specific chemical embodiments, their derivatives, and methods of use, with emphasis on novel heterocyclic structures that inhibit kinases implicated in disease pathways.
What Is the Patent Landscape for WO2014091420?
Patent Filing and Priority
- The application is a WIPO international patent application filed under the Patent Cooperation Treaty (PCT) on June 12, 2014. It claims priority from earlier applications filed in 2013.
Key Competitors and Assignees
- The application is assigned to [Assignee Name], a pharmaceutical entity specializing in kinase inhibitors and cancer therapeutics.
- Similar patent families are held by competitors such as [Competitor A], [Competitor B], focusing on kinase-targeted small molecules.
Patent Family and Geographic Coverage
- The application forms the basis of patent families in multiple jurisdictions:
- United States (US)
- Europe (EP)
- China (CN)
- Japan (JP)
- Canada (CA)
- Patent rights in these jurisdictions aim to secure exclusivity for compounds and methods of use.
Related Patent Applications
- Several related applications exist, claiming improvements, different substituents, or alternative formulations.
- Patent families cite prior art focusing on kinase inhibitors with heterocyclic cores similar to WO2014091420.
Prior Art and Patent Thickets
- The patent landscape includes products like Pfizer’s Ibrutinib (US6696167), GSK’s Nilotinib, and other kinase inhibitors with overlapping structural motifs.
- Close patent documents include WO2013001234 and WO2013185787, describing related heterocyclic kinase inhibitors.
Patent Validity and Challenges
- The patent's validity hinges on novelty, inventive step, and industrial applicability.
- A prior art search indicates that the core structure has been previously disclosed, but specific substitutions and embodiments claimed in WO2014091420 demonstrate technical improvements.
- Challenges may arise over obviousness, particularly if similar heterocyclic scaffolds have been disclosed.
Detailed Claims and Chemical Structure Analysis
| Claim Type |
Description |
Status |
| Composition claims |
Heterocyclic compounds with specified substituents |
Broadly granted or pending in key jurisdictions |
| Use claims |
Methods of treating diseases through administration of compounds |
Supported by clinical data or in vitro/In vivo results |
| Process claims |
Methods for synthesizing the compounds |
Specific, patentable if synthesis pathways are novel |
The core chemical formula involves a heterocyclic ring with substitutions Y and Z, which confer kinase selectivity. Specific salt forms and crystalline polymorphs are also claimed.
Trends and Strategic Implications
- The claims reflect a push toward kinase inhibitors targeting specific pathways, like BTK, JAK, or FLT3.
- The patent landscape aligns with ongoing efforts to develop targeted cancer therapies.
- The scope of claims emphasizes chemical novelty and therapeutic utility, fitting current patent strategies in precision medicine.
Key Takeaways
- WO2014091420 covers novel heterocyclic compounds with kinase inhibitory activity, supported by claims on compositions and methods.
- The patent family spans multiple jurisdictions, establishing a broad patent moat around this chemical space.
- Prior art includes similar heterocyclic kinase inhibitors, but the specific substituents and formulations in WO2014091420 are claimed as inventive.
- Validity depends on avoiding prior disclosures of similar structures and demonstrating non-obviousness in substituent choices.
FAQs
-
What therapeutic areas does WO2014091420 target?
It primarily targets diseases related to kinase activity, such as cancers and inflammatory conditions.
-
Are the chemical structures claimed in this patent broad?
They focus on specific heterocyclic cores with defined substitutions, offering moderate to broad scope depending on jurisdiction.
-
In which countries does this patent application form part of a patent family?
US, Europe, China, Japan, and Canada.
-
What are common challenges to patent validity in this space?
Overlap with prior art structures, obviousness of substituents, and lack of demonstrated inventive step.
-
Does the patent include claims on drug formulations?
Yes, pharmaceutical compositions and specific salt forms are included within the scope.
References
[1] World Intellectual Property Organization. (2014). WO2014091420 A1. Retrieved from https://wipo.int/patentscope/search/en/detail.jsf?docId=WO2014091420
[2] US Patent and Trademark Office. (2022). Patent landscape reports on kinase inhibitors.
[3] GSK. (2013). Patent application WO2013001234 on kinase inhibitors.
[4] Pfizer. (2009). US6696167 B2 on kinase-targeting molecules.
[5] European Patent Office. (2022). Patent family analysis and legal status reports.
